Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR Tcells.

B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma

Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome.

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Sleeping Beauty Transposon‐mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies

Safer CARS

A Transposon and Transposase System for Human Application

Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy.

Context-aware synthetic biology by controller design: Engineering the mammalian cell.

Advancing together and moving forward: Combination gene and cellular immunotherapies